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We designed a study to describe the characteristics of sequence type 131 (ST131) lineages, including the H30-Rx sublineage,
among a global collection of extended-spectrum -lactamase (ESBL)-producing Escherichia coli isolates from 9 countries col-
lected from 2000 to 2011. A total of 240 nonrepeat isolates from Canada, the United States, Brazil, the Netherlands, France, the
United Arab Emirates (UAE), India, South Africa, and New Zealand were included. Established PCR, sequencing, and typing
methods were used to deﬁne ST131 lineages, H30 and H30-Rx phylogenetic groups, gyrA and parC mutations, virotypes, and
plasmid-mediated quinolone resistance determinants. The majority of the isolates produced CTX-M-15 with aac(6=)-lb-cr, be-
longed to phylogenetic group B2, and were positive for the H30 lineage with the gyrA1AB and parC1aAB mutations. ST131
showed 15 distinct pulsotypes; 43% of the isolates belonged to four pulsotypes, with a global distribution. Seventy-ﬁve percent of
the ST131 isolates belonged to H30-Rx; this sublineage was present in all the countries and was associated with multidrug resis-
tance, blaCTX-M-15, aac(6=)-lb-cr, and virotypes A and C. The H41 lineage was negative for the ST131 pabB allele-speciﬁc PCR. The
multidrug-resistant H30-Rx sublineage poses an important public health threat due to its global distribution, association with
virotype C, and high prevalence among ST131 isolates that produce CTX-M-15.
Extended-spectrum -lactamases (ESBLs) belonging to theTEM and SHV families were the predominant types of ESBLs
during the 1980s and early 1990s (1). However, since the late
1990s, CTX-M-lactamases have emerged worldwide among En-
terobacteriaceae, in particular Escherichia coli, and have become
the most prevalent and widespread type of ESBL in the world (2).
CTX-M-producing E. coli organisms are important causes of
community-onset urinary tract infections, bacteremia, and intra-
abdominal infections (3). Currently, the most widespread and
prevalent type of CTX-M enzyme is CTX-M-15 (4).
In 2008, E. coli sequence type 131 (ST131) containing CTX-
M-15 was simultaneously identiﬁed in nine countries, spanning
three continents (5, 6). The intercontinental dissemination of this
ST has contributed immensely to the worldwide emergence of
CTX-M-15-producing E. coli (4). Compared to other ESBL-pro-
ducing E. coli organisms, ST131 isolates with CTX-M--lactamases
are more likely to be resistant to antibiotics and cause community-
acquired urinary tract infections (7). Several in vitro studies suggest
that a unique combination of antimicrobial resistance and virulence
factors seem to give ST131 a competitive advantage over other E. coli
ST, most likely promoting its clonal expansion and dominance
over less virulent and/or more susceptible isolates (8, 9).
The global distribution of ST131 reﬂects the repeated selection
of local variants that have acquired certain IncF resistance plas-
mids carrying genes that encodeCTX-Ms (10). However, Johnson
and colleagues have shown that the expansion of the H30 lineage
within ST131 has contributed signiﬁcantly to the spread of ST131
among ﬂuoroquinolone-resistant E. coli isolates in the United
States (11).
Blanco and colleagues (12) recently introduced a system for
classifying ST131 into 4 groups or virotypes (i.e., A, B, C, and D)
that is based on the distribution of four distinctive virulence fac-
tors, namely, afa FM955459 (Afa/Dr adhesion), iroN (catecholate
siderophore receptor), ibeA (invasion of brain endothelium), and
sat (secreted autotransporter toxin). They reported that virotypes
A and Bwere associatedwithmultidrug resistance, the presence of
CTX-M-15, and the plasmid-mediated quinolone determinant
aac(6=)-lb-cr. Virotype C had a global distribution (i.e., was pres-
ent in 8 countries, including Spain, France, Portugal, Switzerland,
the United States, Canada, South Korea, and Lebanon) and was
statistically associated with a higher frequency of infection (12).
There is limited information regarding the global distribution,
virotypes, and characteristics of ST131 lineages that produce ES-
BLs. We designed a study to describe the characteristics of ST131
lineages, including the H30-Rx sublineage, from a global collec-
tion of ESBL-producing ST131 isolates from 9 countries collected
in 2000 and 2011.
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MATERIALS AND METHODS
Bacterial isolates. We studied a total of 240 nonrepeat ESBL-producing
ST131 E. coli isolates recovered between 2000 and 2010, from 9 different
countries, spanning 4 continents: Canada (Victoria [n  5], Vancouver
[n  8], Calgary [n  62], Edmonton [n  3], Medicine Hat [n  4],
Regina [n 12], Winnipeg [n 11], Toronto [n 10], Brampton [n
13], Ottawa [n 7], Montreal [n 4]), the United States (Chicago, n
16), Brazil (Rio de Janeiro, n 2), the Netherlands (Rotterdam [n 8],
Delft [n 1], Gouda [n 5]), France (Paris, n 4), United Arab Emir-
ates (AbuDhabi, n 8), India (Vellore, n 8), SouthAfrica (Cape Town,
n 12), andNewZealand (Auckland, n 37). Nonrepeat clinical isolates
from previous studies (i.e., from Canada [13, 14], the United States [15],
Brazil [16], the Netherlands [17], and South Africa [18]), as well as re-
cently acquired isolates from India, France, the United Arab Emirates
(UAE), and New Zealand, were included in this study.
Antimicrobial susceptibility testing. MICs were determined with the
Vitek 2 instrument (Vitek AMS; bioMérieux Vitek Systems, Inc., Hazel-
wood,MO) that included the following drugs: amoxicillin-clavulanic acid
(AMC), piperacillin-tazobactam (TZP), ciproﬂoxacin (CIP), gentamicin
(GEN), tobramycin (TOB), amikacin (AMK), imipenem (IPM), mero-
penem (MEM), and trimethoprim-sulfamethoxazole (SXT). Throughout
this study, the results were interpreted using the 2012 CLSI criteria for
broth dilution (19).
ESBL screening and conﬁrmation testing.The presence of ESBLswas
detected in clinical E. coli isolates by using the 2009 CLSI criteria for ESBL
screening and conﬁrmation tests (19).
-Lactamase gene identiﬁcation. Isoelectric focusing, PCR ampli-
ﬁcation, and sequencing for blaCTX-M, blaOXA, blaTEM, and blaSHV were
carried out on the isolates with a GeneAmp 9700 thermal cycler (Ap-
plied Biosystems, Norwalk, CT) using PCR conditions and primers as
previously described (20). The isolates were presumed to produce
whichever ESBL was encoded by the ESBL gene they were found to
contain.
Plasmid-mediated quinolone resistance determinants, phyloge-
netic groups, and virotypes. Ampliﬁcation of the qnrA, qnrS, and qnrB
genes was undertaken in all ESBL-positive isolates with multiplex PCR
(21). aac(6=)-Ib and qepA were ampliﬁed in a separate PCR using primers
and under conditions as previously described (22, 23). The variant
aac(6=)-Ib-cr was further identiﬁed by digestion with BstF5I (New Eng-
land BioLabs, Ipswich, MA). The ESBL-positive isolates were assigned to
one of the fourmain E. coli phylogenetic groups (A, B1, B2, orD) by use of
a multiplex PCR-based method (24). The 4 main virotypes in ST131 were
determined with a multiplex method recently described by Blanco and
colleagues (12).
Pulsed-ﬁeld gel electrophoresis.The genetic relatedness of the ESBL-
producing isolates was examined by pulsed-ﬁeld gel electrophoresis
(PFGE) following the extraction of genomicDNAanddigestionwithXbaI
using the standardized E. coli (O157:H7) protocol established by the Cen-
ters for Disease Control and Prevention, Atlanta, GA (25). Cluster desig-
nation was based on isolates showing approximately 80% relatedness,
which corresponds to the “possibly related (4 to 6 bands difference)”
criterion of Tenover et al. (26).
Identiﬁcationof ST131andﬁmH, gyrA, andparC sequencing.Estab-
lished PCR methods were used to deﬁne the ST131 lineages and the
H30-Rx sublineage among the ESBL isolates (11, 27, 28). ﬁmH (type 1
ﬁmbrial adhesion), gyrA, and parC subtyping were performed as previ-
ously described (11).Multilocus sequence typing (MLST)was undertaken
on all isolates using seven conserved housekeeping genes (adk, fumC,
gyrB, icd, mdh, purA, and recA) (see http://mlst.warwick.ac.uk/mlst/dbs
/Ecoli).
Statistical methods. Analysis was performed using Stata version 10.0
(StataCorp, College Station, TX). Chi-square and Fisher’s exact tests were
used to compare group categorical data. P values of 0.05 were consid-
ered signiﬁcant.
RESULTS
Bacterial isolates and susceptibilities. A total of 240 ESBL-pro-
ducing E. coli ST131 isolates were included in the study; 91 (38%)
were recovered from urine samples, 134 (56%) from blood sam-
ples, 2 (1%) from intra-abdominal specimens, 4 (2%) from
wound swabs, 2 (1%) from respiratory specimens, and 7 (3%)
from rectal swabs. One hundred eighty-one (76%) of these spec-
imens were submitted from community collection sites, and 59
(25%) were from hospitals.
Of the 240 study isolates, 173 (72%) were nonsusceptible (i.e.,
intermediate or resistant) to SXT, 153 (64%) to AMC, 106 (44%)
to TZP, 166 (69%) to TOB, 120 (50%) to GEN, 96 (40%) to AMK,
and 226 (94%) to CIP. No resistance to ERT or IPM was detected.
-Lactamases, PMQRdeterminants, and phylogenetic groups.
Of the 240 ST131 ESBL-producing E. coli isolates, 193 (80%) pro-
duced CTX-M-15, 40 (17%) produced CTX-M-14, 1 (0.5%) pro-
ducedCTX-M-24, 2 (1%)producedCTX-M-27, 3 (1%)produced
CTX-M-3, and 1 (0.5%) produced TEM-52. One hundred ﬁfty-
one (63%) of the ESBL E. coli isolateswere positive for aac(6=)-lb-cr,
and 6 (3%) were positive for aac(6=)-lb-cr and qnrB1. None of the
other types of plasmid-mediated quinolone resistance (PMQR) de-
terminants were detected. All isolates belonged to phylogenetic
group B2.
Pulsed-ﬁeld gel electrophoresis and virotypes. PFGE identi-
ﬁed 15 clusters of E. coli (n 230) that were designated pulsotypes
A (n 8), B (n 20), C (n 11), D (n 22), E (n 5), F (n
7), G (n 11), H (n 20), I (n 10), J (n 17), K (n 29), L
(n 38), M (n 14), N (n 4), and O (n 14) (Table 1). The
remaining ESBL-producing isolates (n 10 and referred to as NR
[not related]) were not clonally related, i.e., they exhibited PFGE
proﬁleswith60% similarity and did not showpatterns similar to
those from pulsotypes A to O. Interestingly, certain pulsotypes
(e.g., H, J, K, and L) had a global distribution, while other pulso-
types (e.g., A, E, F, and N) tended to be more localized (Table 1).
Pulsotypes A to K, N, and O belonged to virotype C, and pulso-
types L and M belonged to virotype A (Table 1). Two isolates from
the NR group produced CTX-M-15 and TEM-52 and belonged
to virotype D, while the remaining NR isolates belonged to
virotype C.
ST131 and ﬁmH, gyrA, and parC sequencing. The majority of
ST131 (220/240 [92%]) isolates belonged to the H30 lineage, and
181/220 (82%) H30 isolates belonged to the H30-Rx sublineage
(Table 1). The remaining ﬁmH types belonged to H22 (n  2),
H35 (n  4), and H41 (n  14). The H30 lineage comprised 13
different pulsotypes (i.e., A to M), while the H35 and H41 lineages
belonged to pulsotypes N and O, respectively (Table 1). The H22
isolates were not clonally related to each other and did not show
patterns similar to those from H30, H35, or H41. The H30-Rx
sublineage was present in 11 pulsotypes (Table 1).
Among the 240 ST131 isolates, sequence analysis of the gyrA
and parC genes identiﬁed 2 gyrA alleles and 3 parC alleles (Table
1). The CIP-susceptible isolates (n 14) were negative for PMQR
determinants and belonged to the H41 (n 13) and H22 (n 1)
ﬁmH lineages. Seven of the CIP-susceptible isolates contained the
putative ancestor allele of gyrA (i.e., gyrA1) and the parC variant
with 1 silentmutation (i.e., parC1b). The remaining 7CIP-suscep-
tible isolates (MICs, 0.12 to 0.5g/ml) contained the gyrA1A allele
(i.e., one amino acid replacement mutation [Ser-83-Leu]) com-
bined with the parC1b allele.
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In contrast, the majority of CIP-nonsusceptible isolates were
positive for aac(6=)-lb-cr (156/226 [69%]), belonged to the H30
(n  220), H35 (n  4), H41 (n  1), and H22 (n  1) ﬁmH
lineages, and possessed the gyrA allele named gyrA1AB (i.e., dif-
fered from gyrA1A by the distinct secondary mutation Asp-87-
Asn) and the parC variant named parC1aAB (i.e., parC1a plus the
replacement mutations Ser-80-Ile and Glu-85-Val) (11). The H41
CIP nonsusceptible isolate contained the gyrA1AB and parC3A
alleles (11).
The antimicrobial susceptibilities, PMQR determinants, ESBL
types, and virotypes of ST131, H30, and H30-Rx are shown in
Table 2. ST131 was divided into 3 groups according to H30 and
H30-Rx status: group 1 was isolates that were negative for H30
(non-H30), group 2 was isolates that were positive for H30 but
negative for H30-Rx (H30 non-Rx), and group 3 was isolates that
were positive for both H30 and H30-Rx (H30-Rx). H30-Rx iso-
lates were signiﬁcantly more likely to be resistant to various anti-
microbial agents, to be positive for aac(6=)-lb-cr and blaCTX-M-15,
and to belong to virotype A (Table 2). H30 non-Rx isolates were
more likely to be positive for blaCTX-M-14 and belong to virotype C.
DISCUSSION
E. coli ST131 is known to cause extraintestinal infections, as its
isolates are ﬂuoroquinolone resistant (FQ-R) and associated with
ESBL production most often due to CTX-M-15 (14, 27, 29).
ST131 is not a single entity and can be subdivided into different
clusters by other typing methods. Previous studies have shown
that ST131 isolates with similar pulsotypes (i.e., 80% related-
ness) can be present in different regions or countries (6, 10, 30).
However, the same studies have also shown that ST131 isolates
with different pulsotypes (80% relatedness) can be present in
the same location (6, 30). These studies have included relatively
few isolates with limited geographical origins and time periods.
Johnson and colleagues (31) addressed these issues when they
studied 579 ST131 isolates from various countries and diverse
sources (humans, animals, and the environment) that spanned
from 1967 to 2009. They concluded that ST131 is highly diverse at
the pulsotype level, but a small number of pulsotypes predomi-
nate internationally, and these high-frequency pulsotypes had
emerged within the last decade (31). A previous study from Cal-
TABLE 1 The molecular characteristics of different pulsotypes among a global collection of ST131 isolates that produce extended-spectrum
-lactamases
Pulsotype
(n)a Isolate origin(s) -Lactamase(s) (n)
PMQRb
determinant(s)
(n) Virotype
ﬁmH
lineage
H30-Rx
(n) gyrA allele(s) parC allele(s)
A (8) Canada, New Zealand CTX-M-15 (8) aac(6=)-lb-cr (6) C H30 8 gyrA1AB parC1aAB
B (20) Canada, France, South
Africa, New Zealand
CTX-M-14 (20) aac(6=)-lb-cr (2) C H30 0 gyrA1AB parC1aAB
C (11) Canada, India, South Africa CTX-M-15 (11) aac(6=)-lb-cr (10) C H30 11 gyrA1AB parC1aAB
D (22) Canada, New Zealand CTX-M-15 (22) aac(6=)-lb-cr (22) C H30 22 gyrA1AB parC1aAB
E (5) Canada CTX-M-14 (2) CTX-M-24 (1)
CTX-M-27 (2)
Negc C H30 0 gyrA1AB parC1aAB
F (7) Canada, New Zealand CTX-M-15 (7) aac(6=)-lb-cr (4) C H30 7 gyrA1AB parC1aAB
G (11) Canada, United States,
South Africa
CTX-M-15 (11) aac(6=)-lb-cr (8) C H30 11 gyrA1AB parC1aAB
H (20) Canada, United States, South
Africa, New Zealand, UAE
CTX-M-15 (20) aac(6=)-lb-cr (19) C H30 20 gyrA1AB parC1aAB
I (10) Canada, United States,
New Zealand
CTX-M-15 (10) aac(6=)-lb-cr (4) C H30 10 gyrA1AB parC1aAB
J (17) Canada, United States, South
Africa, UAE, New
Zealand, the Netherlands
CTX-M-15 (12), CTX-M-14 (5) aac(6=)-lb-cr (10)
aac(6=)-lb-
cr qnrB (3)
C H30 12 gyrA1AB parC1aAB
K (29) Canada, United States, UAE,
South Africa, New
Zealand, India
CTX-M-15 (28), CTX-M-14 (1) aac(6=)-lb-cr (23) C H30 28 gyrA1AB parC1aAB
L (38) Canada, United States, UAE,
South Africa, Brazil, the
Netherlands, India
CTX-M-15 (36), CTX-M-3 (2) aac(6=)-lb-cr (30) A H30 38 gyrA1AB parC1aAB
M (14) Canada, India, South Africa,
the Netherlands
CTX-M-15 (14) aac(6=)-lb-cr (8)
aac(6=)-lb-
cr qnrB (2)
A H30 14 gyrA1AB parC1aAB
N (4) Canada CTX-M-15 (4) aac(6=)-lb-cr (3) C H35 0 gyrA1AB parC1aAB
O (14) Canada, France, the
Netherlands, New Zealand
CTX-M-15 (4), CTX-M-3 (1),
CTX-M-14 (9)
Neg C H41 0 gyrA1AB,
gyrA1A
parC3A,
parC1b
NR (10) Canada, Brazil, United
States, South Africa, New
Zealand
CTX-M-15 (6), CTX-M-14 (3),
TEM-52 (1)
aac(6=)-lb-cr (2),
aac(6=)-lb-
cr qnrB (1)
C, D H30,
H22
0 gyrA1AB
gyrA1A
parC1aAB,
parC1b
a The isolates that belonged to pulsotypes A to O had80% similar PFGE proﬁles among the isolates of each pulsotype. The remaining ESBL-producing isolates referred to as NR
(not related) were not clonally related, i.e., they exhibited60% similar PFGE proﬁles and did not show patterns similar to those from pulsotypes A to O.
b PMQR, plasmid-mediated quinolone resistance.
c Neg, negative.
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gary, Canada, over an 11-year period (2000 to 2010) showed that
a distinct pulsotype of ST131 (named A5 in that study) was re-
sponsible for the signiﬁcant increase in ESBL-producing E. coli
isolates that had been causing bloodstream infections since 2007
(14).
Our current study identiﬁed 15 pulsotypes among 240 human
ESBL-producing ST131 isolates recovered from 9 different coun-
tries, spanning 4 continents, between 2000 and 2010. Our results
were similar to the pulsotype results reported by Johnson et al.
(31): 43% of the isolates from our study belonged to four distinct
pulsotypes (e.g., H, J, K, and L), with a global distribution (i.e.,
were present in 5 different countries and named international
pulsotypes). The remaining 11 pulsotypes tended to be more lo-
calized to certain countries and were named localized pulsotypes.
We do acknowledge that the localized pulsotypes may actually be
more widely disseminated internationally due to sampling bias, as
small numbers of isolateswere sampled fromBrazil, India, France,
and UAE. One of the international pulsotypes (i.e., pulsotype L)
was identical to the Calgary A5 pulsotype and was present in Can-
ada (i.e., Victoria, Vancouver, Edmonton, Medicine Hat, Regina,
Winnipeg, Toronto, Ottawa, Brampton, and Montreal), the
United States, UAE, South Africa, Brazil, the Netherlands, and
India (Table 1).
Most of the pulsotypes from our study belonged to virotype C
(Table 1). Our study supported some of the results reported by
Blanco et al. (12); e.g., virotype A from our study was associated
with the presence of CTX-M-15 and aac(6=)-lb-cr. However, viro-
type C was associated with both CTX-M-15 and CTX-M-14 and
the H35 and H41 lineages (Table 1). Interestingly, the interna-
tional pulsotype L, which was responsible for the signiﬁcant in-
crease in bloodstream infections in Calgary since 2007, belonged
to virotype A and was positive for H30-Rx and aac(6=)-lb-cr.
Whole-genome sequencing of 105 ST131 isolates from 5 coun-
tries revealed that ﬂuoroquinolone resistance was conﬁned to a
single rapidly expanding sublineage designated H30-R (32). Inter-
estingly, H30-R with CTX-M-15 belonged to a single well-deﬁned
clade nested within other H30-R isolates, which was named
H30-Rx due to its more extensive resistance to antimicrobial
agents. A study by Banerjee and colleagues (27) determined the
prevalences of ST131 and its sublineages among 267 E. coli isolates
from the Chicago region. The authors were able to show that
H30-R and H30-Rx were more antimicrobial resistant than and
had distinctive virulence proﬁles compared to those of non-H30
ST131 isolates. Interestingly, the H30-Rx sublineage had the high-
est virulence scores, implying greater virulence potential and pos-
sibly explaining its high prevalence (27).
We believe this is the ﬁrst study to explore the associations of
the H30 lineage and the H30-Rx sublineage of ST131 with differ-
ent virotypes, resistance phenotypes, ESBL types, and the presence
of plasmid-mediated quinolone resistance determinants in a
global collection of E. coli ST131 isolates that produce ESBLs. We
conﬁrmed the association of the H30-Rx sublineage with multi-
drug resistance and the presence of CTX-M-15 (Table 2). We
uniquely identiﬁed the association of H30-Rx with virotypes A
and C and the presence of aac(6=)-lb-cr (Table 2). Isolates of the
H30 lineage that tested negative for Rx (i.e., H30 non-Rx) were
associated with virotype C and the presence of CTX-M-14 (Table
2). The H35 and H41 lineages were linked with virotype C and the
presence of CTX-M-14 and CTX-M-15 (Table 2). However, our
study did not include a sufﬁcient number of non-virotype C iso-
lates to reasonably conclude that H30-Rx isolates were associated
with virotype C. To our knowledge, this is the ﬁrst report that
shows the association of non-H30 with CTX-M-14 due to the H41
lineage.
MLST identiﬁed pulsotype O (n  14) as being from ST131;
however, the PCR for the pabB allele, as described by Clermont
and colleagues (28), was negative for these isolates. Pulsotype O
belonged to the H41 lineage, was positive for virotype C, negative
for plasmid-mediated quinolone resistance determinants, and
present in Canada, France, the Netherlands, and New Zealand
(Table 1). These results were similar to those from a recent study
that determined the virulence properties of the H41 lineage and
also found an association of the H41 lineage with virotype C (33).
The discrepancies observed between the pabB allele-speciﬁc PCR
and MLST for the H41 lineage of ST131 are noteworthy. The H41
lineage belongs to serotype O16:H5, and a PCR method speciﬁc
for the detection of this subgroup was recently published (34).
The H30-Rx sublineage of ST131 is a major drug-resistant
TABLE 2 The antimicrobial susceptibilities, plasmid-mediated
quinolone resistance determinants, extended-spectrum -lactamases,
and different virotypes of ST131 and its H30 and H30-Rx sublineages
Isolate characteristica
No. (%) of isolates in sublineageb:
P
Non-H30
(n 20)
H30 non-Rx
(n 39)
H30-Rx
(n 181)
Collection site 0.5
Hospital 6 (30) 9 (23) 44 (24)
Community 14 (70) 30 (77) 137 (76)
Antimicrobial NS
AMC 4 (20) 16 (41) 133 (73) 0.001
TZP 2 (10) 10 (44) 94 (52) 0.002
CIP 10 (50) 35 (90) 181 (100) 0.001
SXT 1 (5) 19 (49) 153 (85) 0.001
GEN 2 (10) 20 (51) 98 (54) 0.4
TOB 3 (15) 23 (59) 140 (77) 0.01
AMK 1 (5) 11 (28) 84 (46) 0.02
PMQR determinant
aac(6=)-lb-cr 3 (15) 6 (15) 142 (78) 0.001
aac(6=)-lb-cr qnrB 1 (5) 1 (3) 4 (2) NAc
Virotype
A 0 0 52 (29) 0.001
B 0 0 0
C 18 (90) 39 (100) 129 (71) 0.001
D 2 (10) 0 0 NA
Type of ESBL
CTX-M-14 9 (45) 31 (79) 0 0.001
CTX-M-15 9 (45) 5 (13) 179 (99) 0.001
Other CTX-M 1 (5) 3 (8) 2 (1) NA
Other ESBLs 1 (5) 0 0 NA
a NS, nonsusceptible, i.e., either intermediate or resistant; AMC, amoxicillin-clavulanic
acid; TZP, piperacillin-tazobactam; CIP, ciproﬂoxacin; SXT,
trimethoprim-sulfamethoxazole; GEN, gentamicin; TOB, tobramycin; AMK, amikacin;
PMQR, plasmid-mediated quinolone resistance; ESBLs, extended-spectrum -
lactamases.
b Non-H30, ST131 E. coli isolate that was negative for H30; H30 non-Rx, ST131 E. coli
isolate that was positive for H30 but negative for H30-Rx; H30-Rx, E. coli isolate that
was positive for ST131, H30, and H30-Rx.
c NA, not available (too many cells with numbers of5).
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pathogen among ﬂuoroquinolone-resistant E. coli isolates in the
United States (11, 27, 29) and is associated with sepsis (32). Our
study shows that H30-Rx also poses an important public health
threat due to its global distribution, association with virotype C,
and high prevalence among ST131 isolates that produce CTX-M-
15. We urgently need well-designed epidemiological and molecu-
lar studies to understand the dynamics of the transmission, risk
factors, and reservoirs for the E. coli ST131 H30-Rx sublineage.
This will provide insight into the emergence and spread of this
multidrug-resistant sequence type that will hopefully lead to in-
formation essential for preventing the spread of ST131.
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